Sino Biopharmaceutical Limited
1177.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$96.38B
Close$
$6.80
27.1% upside
Current Fair Value
27.1% upsideUndervalued by 27.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $96.38 Billion |
|---|---|
| Enterprise Value | $98.67 Billion |
| Dividend Yield | $0.10 (2.22%) |
| Earnings per Share | $0.13 |
| Beta | 0.63 |
| Outstanding Shares | 18,048,524,000 |
Return
| Return on Equity | 7.34% |
|---|---|
| Return on Assets | 2.87% |
| Return on Invested Capital | 16.90% |
Valuation & Multiples
| P/E Ratio | 34.63 |
|---|---|
| PEG | 2550.55 |
| Price to Sales | 5.35 |
| Price to Book Ratio | 2.68 |
| Enterprise Value to Revenue | 2.93 |
| Enterprise Value to EBIT | 10.39 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$22.29 B
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$19.69 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sino Biopharmaceutical Ltd.
22,838 employees
CEO: Ping Tse Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Che...